E. Haralambie

TL;DR: There is strong evidence that sustained growth suppression of intestinal anaerobic bacteria after clinical sibling marrow transplantation can independently modulate the occurrence of grades II to IV acute GVHD, which is in concordance with previous results from animal transplantation models.

TL;DR: Patients with acute leukemia undergoing remission induction therapy were randomized to receive either a regimen of non-absorbable antimicrobial drugs or of absorbable and non-Absorbable drugs (trimethoprim-sulfamethoxazole [TMP-SMZ] and colistin) for antibacterial prophylaxis for antifungal proplylaxis.

TL;DR: Both drugs showed an effective elimination of gram-negative potential pathogens and Staphylococcus aureus not affecting the anaerobic flora of the gastrointestinal tract and a satisfactory patient compliance could be observed.

TL;DR: The results suggest that the incidence of graft versus host disease may decrease with efficient decontamination of the patients, as well as the supportive care required by the patients was almost equal in both groups.

TL;DR: The results indicate that allogenic marrow transplantation in the fifth decade of life might be associated with a tolerable risk of transplantation-related complications, and this treatment modality may be regarded as first-line therapy for patients in 1st remission of AL or first chronic phase of CML, who show a normal performance status.